{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:25Z","timestamp":1789450465197,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00277-023-05125-5","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T15:52:13Z","timestamp":1676044333000},"page":"937-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Improved V\u03b42+ T cells recovery correlates to reduced incidences of mortality and relapse in acute myeloid leukemia after hematopoietic transplantation"],"prefix":"10.1007","volume":"102","author":[{"given":"Keli","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6437-4330","authenticated-orcid":false,"given":"Jiangying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"5125_CR1","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ (2021) Advances in acute myeloid leukemia. BMJ 375:n2026. https:\/\/doi.org\/10.1136\/bmj.n2026","journal-title":"BMJ"},{"key":"5125_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","volume":"11","author":"L Xu","year":"2018","unstructured":"Xu L, Chen H, Chen J et al (2018) The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol 11:33. https:\/\/doi.org\/10.1186\/s13045-018-0564-x","journal-title":"J Hematol Oncol"},{"key":"5125_CR3","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","volume":"125","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu QF, Xu LP et al (2015) Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 125:3956\u20133962. https:\/\/doi.org\/10.1182\/blood-2015-02-627786","journal-title":"Blood"},{"key":"5125_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/sj.bmt.1705381","volume":"37","author":"DH Kim","year":"2006","unstructured":"Kim DH, Sohn SK, Won DI et al (2006) Rapid helper T-cell recovery above 200 x 106\/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 37:1119\u20131128. https:\/\/doi.org\/10.1038\/sj.bmt.1705381","journal-title":"Bone Marrow Transplant"},{"key":"5125_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.bbmt.2012.10.010","volume":"19","author":"IH Bartelink","year":"2013","unstructured":"Bartelink IH, Belitser SV, Knibbe CA et al (2013) Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant 19:305\u2013313. https:\/\/doi.org\/10.1016\/j.bbmt.2012.10.010","journal-title":"Biol Blood Marrow Transplant"},{"key":"5125_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.bbmt.2013.11.028","volume":"20","author":"YJ Chang","year":"2014","unstructured":"Chang YJ, Zhao XY, Huang XJ (2014) Immune reconstitution after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20:440\u2013449. https:\/\/doi.org\/10.1016\/j.bbmt.2013.11.028","journal-title":"Biol Blood Marrow Transplant"},{"key":"5125_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2781","volume":"10","author":"M Bonneville","year":"2010","unstructured":"Bonneville M, O'Brien RL, Born WK (2010) Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 10:467\u2013478. https:\/\/doi.org\/10.1038\/nri2781","journal-title":"Nat Rev Immunol"},{"key":"5125_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4049\/jimmunol.1800934","volume":"203","author":"AC Hayday","year":"2019","unstructured":"Hayday AC (2019) gammadelta T cell update: adaptate orchestrators of immune surveillance. J Immunol 203:311\u2013320. https:\/\/doi.org\/10.4049\/jimmunol.1800934","journal-title":"J Immunol"},{"key":"5125_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/imm.13542","volume":"167","author":"R Liu","year":"2022","unstructured":"Liu R, Wu N, Gao H et al (2022) Distinct activities of Vdelta1(+) T-cells upon different cytomegalovirus reactivation status after haematopoietic transplantation. Immunology. 167:368\u2013383. https:\/\/doi.org\/10.1111\/imm.13542","journal-title":"Immunology."},{"key":"5125_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/bjh.15037","volume":"180","author":"J Liu","year":"2018","unstructured":"Liu J, Bian Z, Wang X et al (2018) Inverse correlation of Vdelta2(+) T-cell recovery with EBV reactivation after haematopoietic stem cell transplantation. Br J Haematol 180:276\u2013285. https:\/\/doi.org\/10.1111\/bjh.15037","journal-title":"Br J Haematol"},{"key":"5125_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen Z, Prinz I, Dechanet-Merville J et al (2020) Translating gammadelta (gammadelta) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov 19:169\u2013184. https:\/\/doi.org\/10.1038\/s41573-019-0038-z","journal-title":"Nat Rev Drug Discov"},{"key":"5125_CR12","doi-asserted-by":"publisher","first-page":"e1216291","DOI":"10.1080\/2162402X.2016.1216291","volume":"6","author":"A Bertaina","year":"2017","unstructured":"Bertaina A, Zorzoli A, Petretto A et al (2017) Zoledronic acid boosts gammadelta T-cell activity in children receiving alphabeta(+) T and CD19(+) cell-depleted grafts from an HLA-haplo-identical donor. Oncoimmunology 6:e1216291. https:\/\/doi.org\/10.1080\/2162402X.2016.1216291","journal-title":"Oncoimmunology"},{"key":"5125_CR13","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.4049\/jimmunol.1103710","volume":"188","author":"J Gertner-Dardenne","year":"2012","unstructured":"Gertner-Dardenne J, Castellano R, Mamessier E et al (2012) Human Vgamma9Vdelta2 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol 188:4701\u20134708. https:\/\/doi.org\/10.4049\/jimmunol.1103710","journal-title":"J Immunol"},{"key":"5125_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","volume":"39","author":"KT Godder","year":"2007","unstructured":"Godder KT, Henslee-Downey PJ, Mehta J et al (2007) Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 39:751\u2013757. https:\/\/doi.org\/10.1038\/sj.bmt.1705650","journal-title":"Bone Marrow Transplant"},{"key":"5125_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bbmt.2014.09.027","volume":"21","author":"R Perko","year":"2015","unstructured":"Perko R, Kang G, Sunkara A et al (2015) Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia. Biol Blood Marrow Transplant 21:130\u2013136. https:\/\/doi.org\/10.1016\/j.bbmt.2014.09.027","journal-title":"Biol Blood Marrow Transplant"},{"key":"5125_CR16","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3389\/fimmu.2019.01997","volume":"10","author":"L Minculescu","year":"2019","unstructured":"Minculescu L, Marquart HV, Ryder LP et al (2019) Improved overall survival, relapse-free-survival, and less graft-vs.-host-disease in patients with high immune reconstitution of TCR gamma delta cells 2 months after allogeneic stem cell transplantation. Front Immunol 10:1997. https:\/\/doi.org\/10.3389\/fimmu.2019.01997","journal-title":"Front Immunol"},{"key":"5125_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jtct.2021.06.003","volume":"27","author":"E Klyuchnikov","year":"2021","unstructured":"Klyuchnikov E, Badbaran A, Massoud R et al (2021) Enhanced immune reconstitution of gammadelta T cells after allogeneic stem cell transplantation overcomes the negative impact of pretransplantation minimal residual disease-positive status in patients with acute myelogenous leukemia. Transplant Cell Ther 27:841\u2013850. https:\/\/doi.org\/10.1016\/j.jtct.2021.06.003","journal-title":"Transplant Cell Ther"},{"key":"5125_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"5125_CR19","doi-asserted-by":"publisher","first-page":"E659","DOI":"10.1002\/ajh.24910","volume":"92","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Zhao XS, Wang Y et al (2017) Effects of pre- and post-transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen-matched or mismatched related donor allografts. Am J Hematol 92:E659\u2013E661. https:\/\/doi.org\/10.1002\/ajh.24910","journal-title":"Am J Hematol"},{"key":"5125_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41409-018-0300-8","volume":"54","author":"J Liu","year":"2019","unstructured":"Liu J, Ma R, Liu YR et al (2019) The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplant 54:567\u2013577. https:\/\/doi.org\/10.1038\/s41409-018-0300-8","journal-title":"Bone Marrow Transplant"},{"key":"5125_CR21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, Chang YJ, Xu LP et al (2014) Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 124:843\u2013850. https:\/\/doi.org\/10.1182\/blood-2014-03-563130","journal-title":"Blood"},{"key":"5125_CR22","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1200\/JCO.2015.63.8817","volume":"34","author":"YJ Chang","year":"2016","unstructured":"Chang YJ, Xu LP, Wang Y et al (2016) Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft-versus-host disease after haploidentical transplantation. J Clin Oncol 34:1855\u20131863. https:\/\/doi.org\/10.1200\/JCO.2015.63.8817","journal-title":"J Clin Oncol"},{"key":"5125_CR23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","volume":"19","author":"B Silva-Santos","year":"2019","unstructured":"Silva-Santos B, Mensurado S, Coffelt SB (2019) gammadelta T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat Rev Cancer 19:392\u2013404. https:\/\/doi.org\/10.1038\/s41568-019-0153-5","journal-title":"Nat Rev Cancer"},{"key":"5125_CR24","doi-asserted-by":"publisher","unstructured":"Liu J, Gao H, Xu LP et al (2020) Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vdelta2(+) T cells activities after hematopoietic transplantation for blood malignancies. J Immunother Cancer 8. https:\/\/doi.org\/10.1136\/jitc-2019-000208","DOI":"10.1136\/jitc-2019-000208"},{"key":"5125_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41409-018-0351-x","volume":"54","author":"A Bondanza","year":"2019","unstructured":"Bondanza A, Ruggeri L, Noviello M et al (2019) Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. Bone Marrow Transplant 54:867\u2013876. https:\/\/doi.org\/10.1038\/s41409-018-0351-x","journal-title":"Bone Marrow Transplant"},{"key":"5125_CR26","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1200\/JCO.2003.11.066","volume":"21","author":"N Aladjidi","year":"2003","unstructured":"Aladjidi N, Auvrignon A, Leblanc T et al (2003) Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89\/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 21:4377\u20134385. https:\/\/doi.org\/10.1200\/JCO.2003.11.066","journal-title":"J Clin Oncol"},{"key":"5125_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR et al (2015) Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant 21:454\u2013459. https:\/\/doi.org\/10.1016\/j.bbmt.2014.11.007","journal-title":"Biol Blood Marrow Transplant"},{"key":"5125_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00277-021-04674-x","volume":"101","author":"P Zhao","year":"2022","unstructured":"Zhao P, Ni M, Ma D et al (2022) Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. Ann Hematol 101:119\u2013130. https:\/\/doi.org\/10.1007\/s00277-021-04674-x","journal-title":"Ann Hematol"},{"key":"5125_CR29","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00277-022-04930-8","volume":"101","author":"T Dong","year":"2022","unstructured":"Dong T, Wu N, Gao H et al (2022) CD277 agonist enhances the immunogenicity of relapsed\/refractory acute myeloid leukemia towards Vdelta2(+) T cell cytotoxicity. Ann Hematol 101:2195\u20132208. https:\/\/doi.org\/10.1007\/s00277-022-04930-8","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05125-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05125-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05125-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T21:27:31Z","timestamp":1678397251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05125-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5125"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05125-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"22 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. The study protocols have been approved by the Ethical Committee of Peking University Institute of Hematology. All patients signed the consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}